Over the last 2 decades, research criteria for AD have integrated biomarkers of amyloid plaques and NFTs (Aβ, T‐Tau, and p‐Tau) in the diagnostic process (Henriques et al., 2019). The gene discussed is MAPT; the disease is Alzheimer disease.